Ashy Noha, Nguyen Thanh-Nga, Denhaerynck Kris, Gharaibeh Mahdi, Alhossan Abdulaziz, Vancayzeele Stefaan, Brié Heidi, Aerts Ann, MacDonald Karen, Abraham Ivo
College of Pharmacy, King Abdulaziz University, P.O. Box 80200, Jeddah 21589, Saudi Arabia.
Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, 1295 N Martin, Tucson, AZ 85721, USA.
Int J Chronic Dis. 2017;2017:9842450. doi: 10.1155/2017/9842450. Epub 2017 Sep 25.
We pooled data from 6 valsartan-related studies including 3,658 diabetic and 11,624 nondiabetic patients to evaluate blood pressure (BP) outcomes after approximately 90 days of second- or later-line valsartan treatment. Hierarchical linear and logistic regressions were applied to identify determinants of BP outcomes. Similar reductions in BP values and similar BP control rates were achieved in both groups after approximately 90 days of therapy. The modeling analyses identified several common and different patient- and physician-related determinants of BP outcomes for both groups, many of which are modifiable or clinically manageable. Through varying in terms of association and influence between the diabetic and nondiabetic groups, patient-related determinants included age, BP at diagnosis of hypertension, risk factors, valsartan regimen, concomitant antihypertensive treatment, and adherence; and physician-related determinants included gender, years in practice, and hypertension management. In summary, in both diabetic and nondiabetic patients, the use of valsartan-centric treatment regimens in second- or later-line antihypertensive treatment is associated with significant reductions in BP level and improvement in BP control. The determinants identified in modeling provide guidance to clinicians in the common and differential management of hypertension in diabetic and nondiabetic patients.
我们汇总了6项与缬沙坦相关的研究数据,其中包括3658例糖尿病患者和11624例非糖尿病患者,以评估二线或后续缬沙坦治疗约90天后的血压结局。应用分层线性回归和逻辑回归来确定血压结局的决定因素。治疗约90天后,两组的血压值均有相似程度的降低,血压控制率也相似。模型分析确定了两组血压结局的几个常见和不同的患者及医生相关决定因素,其中许多因素是可改变的或临床上可管控的。患者相关决定因素在糖尿病组和非糖尿病组之间的关联和影响有所不同,包括年龄、高血压诊断时的血压、危险因素、缬沙坦治疗方案、联合抗高血压治疗及依从性;医生相关决定因素包括性别、从业年限和高血压管理。总之,在糖尿病和非糖尿病患者中,二线或后续抗高血压治疗中使用以缬沙坦为中心的治疗方案均与血压水平显著降低及血压控制改善相关。模型分析中确定的决定因素为临床医生对糖尿病和非糖尿病患者高血压的共性和差异管理提供了指导。